Last checked at 
24 Jun 2021 13:30
BIOPHARMA CREDIT PLC
(THE "COMPANY")
RESULT OF GM AND AGM
General Meeting
The Company is pleased to announce that, at the General Meeting held today, both resolutions were put to the meeting and passed on a show of hands.
The proxy votes received in relation to this resolution was as follows:
Resolutions
| Votes For
| % | Votes Against
| % | Votes at Chairman's Discretion | Votes Withheld |
1: To appoint PricewaterhouseCoopers LLP as auditor to the Company
| 603,573,041 | 98.37 | 10,013,980 | 1.63 | 0 | 0 |
2: To authorise the Directors to determine the remuneration of PricewaterhouseCoopers LLP as the auditor
| 613,573,041 | 99.99 | 13,980 | 0.01 | 0 | 0 |
Annual General Meeting
The Company is pleased to announce that, at the Annual General Meeting that was adjourned on 17 June 2021 and reconvened today, Resolution 1 was put to the meeting and passed on a show of hands.
The proxy votes received in relation to this resolution was as follows:
Resolutions
| Votes For
| % | Votes Against
| % | Votes at Chairman's Discretion | Votes Withheld |
1: To receive and accept the annual report and financial statements
| 644,324,577 | 100 | 0 | 0 | 0 | 0 |
24 June 2021
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24